Studying the Safety, Efficacy, & Pharmacokinetic Characteristics of BNCT

Status Recruiting

Clinical Trial Summary

This is a multi-centered, radiation dose escalation, open, exploratory, Phase 1/2a clinical trial on the safety, efficacy and pharmacokinetic characteristics of BNCT in patients with recurrent high-grade gliomas. The Phase I clinical study is to explore the adequate radiation dose level of BNCT based on confirmation of the maximum tolerated dose (radiation dose) of BNCT in patients with recurrent high-grade gliomas and characterize the safety, efficacy and pharmacokinetics. To evaluate the primary objective of tolerability, subject population with history of exposure to a similar treatment recurrent high-grade glioma who received prior standard radiotherapy will be recruited. The Phase IIa is to confirm the efficacy and safety after irradiation of radiation dose confirmed in the Phase I clinical study. To evaluate the primary objective of efficacy, subject population with glioblastoma (The 2021 WHO Classification of Tumors of the Central Nervous System, Glioblastoma IDH-wild type, WHO Grade 4) will be recruited.

Clinical Trial Description

The subject receives the study drug administration and neutron irradiation in the BNCT clinic with all procedures performed under the control by the investigator affiliated to the study site. 500 mg/kg of the study drug is intravenously administered over 3 hours at a constant rate and neutron irradiation starts at 1 hour after the end of the study drug administration according to the previously established neutron irradiation plan. All patients will be evaluated for response using magnetic resonance imaging (MRI) using RANO and modified RANO criteria. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05737212
Study type	Interventional
Source	Dawonmedax Co., Ltd.
Contact	Moonkyoung Kim
Phone	82-10-9905-6582
Email	gomgomhi4@dawonmedax.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	December 5, 2022
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05577091` - Tris-CAR-T Cell Therapy for Recurrent Glioblastoma	Phase 1
Recruiting	`NCT05284643` - Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma	N/A
Recruiting	`NCT05039281` - Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma	Phase 1/Phase 2
Recruiting	`NCT04988750` - Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients	N/A
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Completed	`NCT00503204` - Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour	Phase 1
Completed	`NCT03216499` - HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma	Phase 2
Not yet recruiting	`NCT04717999` - Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma	N/A
Not yet recruiting	`NCT05540275` - Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	Phase 2
Recruiting	`NCT04528680` - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma	Phase 1/Phase 2
Active, not recruiting	`NCT04044937` - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms	Phase 2
Recruiting	`NCT04888611` - Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma	Phase 2
Completed	`NCT00390299` - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	Phase 1
Recruiting	`NCT05463848` - Surgical Pembro +/- Olaparib w TMZ for rGBM	Phase 2
Active, not recruiting	`NCT04479241` - LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma	Phase 2
Active, not recruiting	`NCT00777153` - Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma	Phase 3
Withdrawn	`NCT05017610` - Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma	Early Phase 1
Recruiting	`NCT04323046` - Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults	Phase 1
Active, not recruiting	`NCT05324501` - A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma	Phase 1
Withdrawn	`NCT05666349` - Reirradiation and Niraparib in Patients With Recurrent Glioblastoma	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms